BookCarlos Cervera, Jose Maria Aguado, editors.
Summary: This book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.
Contents:
Intro
Preface
Contents
Part I: Overview of the Epidemiology, Risk and Prevention of Infections
1: Overview of the Risk of Infection Associated with Biologic and Target Therapies
Overview of Targeted and Biological Therapies
Monoclonal Antibodies and Related Agents
Small-Molecule Enzyme Inhibitors
Assessment of the Risk of Infection
References
2: Timeline and Infectious Disease Evaluation of Candidates to New Therapies
Introduction
Timeline of Infectious Complications in Patients on Biologic and Targeted Drugs Evaluation and Prevention of Infectious Complications in Patients on Biologic and Targeted Treatment
Conclusion
References
3: Safety and Efficacy of Vaccines in Patients on Targeted and Biologic Therapies
Summary Table
Evidence Summary by Medication Class
TNF-Alpha Inhibitors and Abatacept
Hepatitis B (HBV) Vaccine
Pneumococcal Vaccine
Influenza Vaccine
Live Vaccines
IL-1 Inhibitors
IL-6
HBV Vaccine
Pneumococcal Vaccine
Influenza
Tetanus
Live Vaccines
IL-12/23
IL-17
Eculizumab
VEGF Inhibitors (Bevacizumab, Aflibercept) VEGF-R Inhibitors (Sorafenib, Sunitinib, Axitinib, Pazopanib, Regorafenib, Vandetanib, Cabozantinib, Ramucirumab)
ErbB2/HER2 Inhibitors (Trastuzumab, Pertuzumab)
ErbB Receptor Tyrosine Kinases (Erlotinib, Gefitinib, Afatinib, Osimertinib, Lapatinib, Neratinib)
BCR-ABL Tyrosine Kinase Inhibitors (Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib)
Burton Tyrosine Kinase Inhibitors (Ibrutinib, Acalabrutinib)
PI3K Inhibitors Idelalisib, Buparlisib, Rigosertib, Duvelisib
Janus Kinase Inhibitors (Ruxolitinib, Tofacitinib, Baricitinib)
Pneumococcal Vaccine
Influenza
Tetanus Live Zoster Vaccine
mTOR Inhibitors (Everolimus, Temsirolimus)
Anti-CD20 (Rituximab, 90Y-Ibritumomab Tiuxetan, Ofatumumab, Ocrelizumab, Veltuzumab, 131I-Tositumomab, Obinutuzumab, Ocaratuzumab, Ublituximab)
Pneumococcal Vaccine
Influenza
Hepatitis B Vaccine
Tetanus
Varicella
Alemtuzumab
Anti CD-38 (Daratumumab, Isatuxumab)
CTLA-4 Inhibitors (Ipilimumab, Tremelimumab)
PD-1 and PD-1 Ligand Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab)
Influenza Vaccine
Recombinant Zoster Vaccine
LFA-3 Inhibitor (Alefacept) Alpha 4-Integrin and LFA-1 Inhibitors (Natalizumab, Vedolizumab, Efalizumab)
Influenza Vaccine
Other Vaccines
Live Vaccines
Sphingosine 1-Phosphate Receptor Inhibitor (Fingolimod, Siponimod)
Proteosome Inhibitors (Bortezomib, Carfilzomib, Ixazomib)
References
4: Travel and Risk of Infections
Introduction
Infectious Diseases and Risks Factors for Travelers
Modes of Transmission of Infections
Risks Factors for Travelers
Common Infectious Diseases in Travelers
Gastrointestinal Infections
Respiratory Infections
Vector-Borne Infections
Skin Infections